LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes
- LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”).
- LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system.
- The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.
The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing therapies rather than replacing them.
In short, the compound works around a novel concept known as activation lethality, where it triggers cancer cells to be more vulnerable and susceptible to these therapies and stops their ability to repair themselves once they’ve been damaged. This makes the compound specifically useful against difficult-to-treat cancers, as these will often survive radiation and chemotherapy by repairing DNA damage, a process which LB-100 aims to help prevent.
Without solutions like LB-100, many cancers would remain resistant to common therapies, which inevitably leads to worse outcomes for patients. Also, while some direct natural PP2A inhibitors do exist, these are often too toxic to use safely in treatment.
In addition to being effective and helpful in the fight against cancer, LB-100 has also demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies.
Currently, the compound is being evaluated in numerous leading cancer research institutions, including MD Anderson Cancer Center, the Netherlands Cancer Institute, and international research groups. Ongoing trials for LB-100 include combining it with immunotherapy in metastatic MSI-low colon cancer and ovarian clear cell carcinoma, and combination therapy alongside chemotherapy in advanced soft tissue sarcoma.
These studies are being done in collaboration with leading academic cancer centers and industry partners, highlighting LIXTE’s emphasis on externally validated clinical execution.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- LIXTE’s lead compound, LB-100, is the world’s first and only clinical-stage inhibitor of protein phosphatase 2A (“PP2A”).
- LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer’s internal repair system.
- The compound has demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by over 25 published preclinical and translational studies so far.
LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.
The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing therapies rather than replacing them.
In short, the compound works around a novel concept known as activation lethality, where it triggers cancer cells to be more vulnerable and susceptible to these therapies and stops their ability to repair themselves once they’ve been damaged. This makes the compound specifically useful against difficult-to-treat cancers, as these will often survive radiation and chemotherapy by repairing DNA damage, a process which LB-100 aims to help prevent.
Without solutions like LB-100, many cancers would remain resistant to common therapies, which inevitably leads to worse outcomes for patients. Also, while some direct natural PP2A inhibitors do exist, these are often too toxic to use safely in treatment.
In addition to being effective and helpful in the fight against cancer, LB-100 has also demonstrated a favorable safety profile in Phase 1 clinical trials and has been supported by more than 25 published preclinical and translational studies.
Currently, the compound is being evaluated in numerous leading cancer research institutions, including MD Anderson Cancer Center, the Netherlands Cancer Institute, and international research groups. Ongoing trials for LB-100 include combining it with immunotherapy in metastatic MSI-low colon cancer and ovarian clear cell carcinoma, and combination therapy alongside chemotherapy in advanced soft tissue sarcoma.
These studies are being done in collaboration with leading academic cancer centers and industry partners, highlighting LIXTE’s emphasis on externally validated clinical execution.
For more information, visit the company website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
